# Kyowa Kirin

Source: https://onco.cc/companies/kyowa-kirin/  
OnCo record `kyowa-kirin` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Kyowa Kirin is a Japanese biopharmaceutical company whose oncology products include mogamulizumab (Poteligeo) for cutaneous T-cell lymphoma and toremifene (Fareston) for metastatic breast cancer.

## Summary

Kyowa Kirin, based in Tokyo, listed as 4151.T and part of the Kirin group, is a Japanese biopharmaceutical company whose oncology products include mogamulizumab, sold as Poteligeo, for cutaneous T-cell lymphoma and toremifene, sold as Fareston, for metastatic breast cancer. It developed the anti-CCR4 antibody mogamulizumab, markets Fareston in the United States, and also sells burosumab as Crysvita and G-CSF products in Japan. OnCo links it to the toremifene drug record. Whether a CCR4 antibody can find uses beyond rare T-cell lymphomas is the open question for its oncology franchise. Toremifene has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Tokyo
- Type: pharma
- Website: https://www.kyowakirin.com
- Ticker: 4151.T

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Kyowa_Kirin
- Official website: https://www.kyowakirin.com

## Connected records

- targets: [CCR4](https://onco.cc/targets/ccr4/)
- drugs: [Burosumab](https://onco.cc/drugs/burosumab/), [Mogamulizumab](https://onco.cc/drugs/mogamulizumab/), [Toremifene](https://onco.cc/drugs/toremifene/)
- trials: [A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms](https://onco.cc/trials/nct07629726/), [A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia](https://onco.cc/trials/nct07623616/), [MAVORIC](https://onco.cc/trials/mavoric/), [UX023T-CL201](https://onco.cc/trials/ux023t-cl201/)
- companies: [MEI Pharma](https://onco.cc/companies/mei-pharma/)
- key papers: [Burosumab for the treatment of tumor-induced osteomalacia (UX023T-CL201)](https://onco.cc/key-papers/paper-ux023t-cl201-jan-de-beur-jbmr-2021/)

---
JSON: https://onco.cc/api/v1/entities/kyowa-kirin.json